生物技术公司R1 Therapeutics近日宣布成功完成新一轮融资。本轮融资由知名投资机构Abingworth、F-Prime Capital与达维塔风投集团（DaVita Venture Group）共同担任联合领投方。同时获得Curie.bio、Symbiosis以及美国肾脏护理公司（U.S. Renal Care）等多家机构的积极参与。
此次融资将用于加速R1 Therapeutics在肾脏疾病治疗领域的创新药物研发进程，推动其前沿疗法从实验室向临床阶段转化。多方资本的注入不仅彰显了市场对肾脏病治疗赛道的信心，也为企业后续发展提供了强有力的资金保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.